Literature DB >> 4113391

Inhibitors of kallikrein in human plasma.

D J McConnell.   

Abstract

Human plasma was fractionated by ammonium sulfate precipitation, DEAE-cellulose chromatography, and Sephadex G-200 gel filtration to determine which method would give the greatest number of clearly separable kallikrein inhibitory peaks. With G-200 gel filtration three peaks could be separated which were demonstrated to contain alpha(2)-macroglobulin, C1 inactivator, and alpha(1)-antitrypsin. No other kallikrein inhibitors could be identified. The fractions containing C1 inactivator and alpha(2)-macroglobulin appeared to be more effective against kallikrein than that containing alpha(1)-antitrypsin. A patient with hereditary angioneurotic edema was shown to have an abnormal C1 inactivator protein capable of interfering with kallikrein's biologic, but not its esterolytic activity. Heat-treated human plasma, a commonly used source of kininogen for experiments with kallikrein, was shown to have kallikrein inhibitory activity.

Entities:  

Mesh:

Substances:

Year:  1972        PMID: 4113391      PMCID: PMC292308          DOI: 10.1172/jci106962

Source DB:  PubMed          Journal:  J Clin Invest        ISSN: 0021-9738            Impact factor:   14.808


  34 in total

1.  Alpha-1-antitrypsin, an inhibitor for thrombin and plasmin.

Authors:  H Gans; B H Tan
Journal:  Clin Chim Acta       Date:  1967-07       Impact factor: 3.786

2.  Inhibition of plasmin activity by alpha-2-macroglobulin.

Authors:  P O Ganrot
Journal:  Clin Chim Acta       Date:  1967-05       Impact factor: 3.786

3.  Dissociation of esterolytic and clotting activities of thrombin by trypsin-binding macroglobulin.

Authors:  G F Lanchantin; M L Plesset; J A Friedmann; D W Hart
Journal:  Proc Soc Exp Biol Med       Date:  1966-02

4.  Separation of kinin-forming factors in human plasma.

Authors:  V Eisen; K L Glanville
Journal:  Br J Exp Pathol       Date:  1969-10

5.  Partial purification of bovine plasma kallikreinogen, its activation by the Hageman factor.

Authors:  S Nagasawa; H Takahashi; M Koida; T Suzuki; J G Schoenmakers
Journal:  Biochem Biophys Res Commun       Date:  1968-08-21       Impact factor: 3.575

Review 6.  Hereditary angioneurotic edema: a clinical survey.

Authors:  V H Donaldson; F S Rosen
Journal:  Pediatrics       Date:  1966-06       Impact factor: 7.124

7.  Inhibitors of kallikrein and other proteinases from animal blood.

Authors:  E Habermann
Journal:  Ann N Y Acad Sci       Date:  1968-06-28       Impact factor: 5.691

8.  Human serum inhibitor of C'1 esterase: identity with alpha-2-neuraminoglycoprotein.

Authors:  J Pensky; H G Schwick
Journal:  Science       Date:  1969-02-14       Impact factor: 47.728

9.  Studies on the prekallikrein (kallikreinogen)--kallikrein enzyme system of human plasma. I. Isolation and purification of plasma kallikreins.

Authors:  R W Colman; L Mattler; S Sherry
Journal:  J Clin Invest       Date:  1969-01       Impact factor: 14.808

10.  The inhibition of plasmin, plasma kallikrein, plasma permeability factor, and the C'1r subcomponent of the first component of complement by serum C'1 esterase inhibitor.

Authors:  O D Ratnoff; J Pensky; D Ogston; G B Naff
Journal:  J Exp Med       Date:  1969-02-01       Impact factor: 14.307

View more
  17 in total

Review 1.  Biological activities of C1 inhibitor.

Authors:  Alvin E Davis; Pedro Mejia; Fengxin Lu
Journal:  Mol Immunol       Date:  2008-07-31       Impact factor: 4.407

Review 2.  Bradykinin formation. Plasma and tissue pathways and cellular interactions.

Authors:  A P Kaplan; K Joseph; Y Shibayama; Y Nakazawa; B Ghebrehiwet; S Reddigari; M Silverberg
Journal:  Clin Rev Allergy Immunol       Date:  1998       Impact factor: 8.667

Review 3.  Postoperative changes in hemostasis analyzed by the serial determination of fibrinopeptides and D-dimer.

Authors:  J Kang; J Kambayashi; M Sakon; T Tsujinaka; T Mori
Journal:  Jpn J Surg       Date:  1989-05

4.  Investigation of the esterolytic activity of human blood plasma after treatment with kaolin and streptokinase.

Authors:  N V Komissarova; O A Gomazkov
Journal:  Bull Exp Biol Med       Date:  1974-08       Impact factor: 0.804

5.  Degradation of human fibrinogen by plasms alpha2-macroglobulin-enzyme complexes.

Authors:  P C Harpel; M W Mosesson
Journal:  J Clin Invest       Date:  1973-09       Impact factor: 14.808

Review 6.  Natural inhibitors of fibrinolysis.

Authors:  D Collen
Journal:  J Clin Pathol Suppl (R Coll Pathol)       Date:  1980

7.  Complement, coagulation and fibrinolytic parameters in hereditary angioedema (HAE).

Authors:  W Cullmann; P M Kövary; N Müller; W Dick
Journal:  Clin Exp Immunol       Date:  1982-09       Impact factor: 4.330

8.  Prostate-specific antigen kallikrein and the heart.

Authors:  Salvatore Patanè
Journal:  World J Cardiol       Date:  2009-12-31

9.  Plasma inhibitors of the components of the fibrinolytic pathway in man.

Authors:  A D Schreiber; A P Kaplan; K F Austen
Journal:  J Clin Invest       Date:  1973-06       Impact factor: 14.808

10.  Contribution of plasma protease inhibitors to the inactivation of kallikrein in plasma.

Authors:  M Schapira; C F Scott; R W Colman
Journal:  J Clin Invest       Date:  1982-02       Impact factor: 14.808

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.